Breast Cancer Research
Whether you have early stage breast cancer or metastatic breast cancer, research can play an important role in your treatment plan, offering you access to leading-edge treatments. It can also play an important role in other peoples’ lives. By participating in a breast cancer clinical trial, you help pave the way to new prevention, detection and treatment strategies that can offer hope to people with cancer.
As an academic medical center, we are involved in some of the most groundbreaking cancer trials available today. By choosing the USC Breast Center for your breast care, you have access to clinical trials that are helping make breast cancer a disease of the past.
- Breast cancer breakthroughs
- Breast cancer clinical trials
- Finding a cure
- Improving detection, treatment, prevention
- National Cancer Institute (NCI) designation
- Understanding breast cancer causes
What our National Cancer Institute designation means
In 1973, USC Norris Comprehensive Cancer Center was designated as one of the country’s original eight comprehensive cancer centers by the National Cancer Institute (NCI), the federal government’s principle agency for cancer research and training. As an NCI-designated cancer center, we anchor the country’s cancer research efforts, making scientific discoveries that are translated into new treatments for people with cancer. The collective work of NCI researchers has led to important medical advances that have increased the number of cancer survivors in the United States and worldwide.
USC Norris cancer research breakthroughs
Our clinician-scientists have been at the forefront of cancer research for more than 40 years, making historic breakthroughs that have changed the way we understand breast cancer and how it’s treated.
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
PRIMARY OBJECTIVES: I. To compare the effect of prophylactic anti-HBV therapy versus upon indication anti-HBV therapy on time-to-adverse liver outcomes of liver failure or liver-related ...Learn More ≫
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
PRIMARY OBJECTIVE: I. To compare the invasive disease-free survival (IDFS) of patients with inflammatory breast cancer receiving concurrent administration of olaparib with standard doses of radiotherapy to the chest ...Learn More ≫
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
PRIMARY OBJECTIVE: I. To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes ...Learn More ≫
A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Surveillance population and ctDNA screening (up to 1000 patients): Clinically high risk, stage II-III, ER positive, HER2-, breast cancer patients who are currently receiving adjuvant endocrine therapy with an ...Learn More ≫
Assessing Health Literacy and Interpreter Use in Radiation Oncology at LAC+USC Medical Center
PRIMARY OBJECTIVE: I. To assess patient health literacy and understanding of critical radiation information during consultation in Spanish and English speaking patient in the department of radiation oncology at Los ...Learn More ≫